What Is the Safety Pharmacology Core Battery (CV, CNS, Respiratory)?

Safety Pharmacology Core Battery studies encompass critical safety studies conducted to evaluate the potential adverse effects of newly developed drug candidates and biotechnological products on vital physiological systems. These studies focus specifically on determining the effects on the cardiovascular system (CV), central nervous system (CNS), and respiratory system.

Recognized by international regulatory authorities as one of the fundamental requirements of the new drug development process, Safety Pharmacology Core Battery studies play a crucial role in evaluating product safety prior to transitioning to clinical trials.

At NanoTox, we provide Safety Pharmacology services in accordance with international standards, leveraging our infrastructure and expert team that adhere to GLP (Good Laboratory Practice) principles.

The Purpose of Safety Pharmacology Studies

The primary purpose of safety pharmacology studies is to identify adverse pharmacological effects that may occur at therapeutic doses or at levels exceeding therapeutic exposure.

Through these studies:

• Effects on vital organ systems are evaluated,
• Safety risks are identified,
• Clinical trial designs are supported,
• Contributions are made to dose selection processes,
• Regulatory requirements are met.

The data obtained assist in making critical decisions during the transition to human studies.

Why Is the Core Battery Important?

International guidelines mandate or strongly recommend the evaluation of three key physiological systems in particular:

• The cardiovascular system,
• The central nervous system,
• The respiratory system.

Adverse effects that may arise in these systems are among the most critical risks in terms of clinical safety.

Cardiovascular (CV) System Assessments

Cardiovascular safety studies aim to evaluate the test substance’s effects on the heart and circulatory system.

The primary parameters evaluated are:

• Heart rate,
• Blood pressure,
• Electrocardiogram (ECG) parameters,
• QT interval assessments,
• Changes in cardiac rhythm,
• Conduction disturbances.

These evaluations contribute to the identification of potential cardiotoxicity risks.

Central Nervous System (CNS) Assessments

Central nervous system safety studies aim to determine the effects of the test substance on neurological functions.

Parameters frequently assessed in this context include:

• Behavioral changes,
• Motor activity,
• Coordination,
• Reflex responses,
• Sensory functions,
• Neurological observations.

These data help in the assessment of potential neurotoxicity risks.

Respiratory System Assessments

Respiratory safety studies evaluate the effects of the test substance on respiratory functions.

The primary parameters examined are:

• Respiratory rate,
• Respiratory volume,
• Minute ventilation,
• Respiratory patterns,
• Changes in respiratory function.

These studies enable the early identification of potential respiratory system risks.

Studies Conducted in Accordance with International Guidelines

Safety Pharmacology studies conducted at NanoTox are carried out in accordance with international regulatory guidelines.

Key reference documents:

• ICH S7A – Safety Pharmacology Studies for Human Pharmaceuticals
• ICH S7B – Nonclinical Evaluation of the Potential for Delayed Ventricular Repolarization
• OECD GLP Principles
• FDA and EMA Safety Guidelines

These standards ensure that the data obtained comply with internationally accepted quality criteria.

Reliable Safety Pharmacology Studies with NanoTox

With its expert toxicology team, advanced laboratory infrastructure, and GLP-compliant operational system, NanoTox conducts Safety Pharmacology Core Battery studies in accordance with international standards.

We support product development programs by providing the reliable cardiovascular, neurological, and respiratory safety data required in drug development processes.

Please contact NanoTox for detailed information about Safety Pharmacology Core Battery studies.